CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. [electronic resource]
Producer: 20201015ISSN:- 2379-3708
- Animals
- Antibody-Dependent Cell Cytotoxicity -- drug effects
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Breast -- pathology
- Breast Neoplasms -- drug therapy
- CD47 Antigen -- antagonists & inhibitors
- Cell Line, Tumor
- Drug Synergism
- Female
- Humans
- Immunity, Innate -- drug effects
- Macrophages -- drug effects
- Mice
- Phagocytosis -- drug effects
- Prognosis
- Receptor, ErbB-2 -- antagonists & inhibitors
- Trastuzumab -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.